Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aldesleukin + interferon alfa
- Development stage
- Unknown
- Lead developer
- Hoag Memorial Hospital Presbyterian
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
aldesleukin + interferon alfa is a combination immunotherapy regimen evaluated for the treatment of metastatic cancer. Aldesleukin is a recombinant form of interleukin-2 (IL-2), a cytokine that plays a central role in the immune response by promoting the proliferation and activation of T lymphocytes and natural killer (NK) cells. Interferon alfa is a type I interferon that exhibits multifaceted anti-tumor activity, including the induction of MHC class I expression on tumor cells to improve recognition by the immune system, direct inhibition of viral replication, and suppression of cell proliferation. This specific outpatient subcutaneous administration protocol was investigated by Hoag Memorial Hospital Presbyterian to assess the efficacy and toxicity of the combined cytokines in patients with advanced malignancies.
- Brand names
- ProleukinRoferon-AIntron A
- Other names
- IL-2 + IFN-alphaInterleukin-2 + Interferon alfa
02
Targets
IL2RB (IL-2 receptor beta chain)IL2RA (Interleukin-2 receptor alpha subunit)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on aldesleukin + interferon alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aldesleukin + interferon alfa.